MX356295B - Análogos de péptido de la hormona de estimulación de alfa-melanocito. - Google Patents

Análogos de péptido de la hormona de estimulación de alfa-melanocito.

Info

Publication number
MX356295B
MX356295B MX2013012525A MX2013012525A MX356295B MX 356295 B MX356295 B MX 356295B MX 2013012525 A MX2013012525 A MX 2013012525A MX 2013012525 A MX2013012525 A MX 2013012525A MX 356295 B MX356295 B MX 356295B
Authority
MX
Mexico
Prior art keywords
peptide analogs
stimulating hormone
alpha
melanocyte stimulating
analogs
Prior art date
Application number
MX2013012525A
Other languages
English (en)
Inventor
A Perricone Michael
Lyle Dzuris John
E Weeden Timothy
E Stefano James
Q Pan Clark
E Edling Andrea
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX356295B publication Critical patent/MX356295B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a análogos de péptido estables de la hormona de estimulación de alfa-melanocito (a-MSH) nativa que tienen selectividad para el receptor de melanocortina 1 (MC1R) También se proporcionan en la presente preparaciones farmacéuticas de los análogos de péptido de a-MSH así como métodos para utilizar estos análogos en el tratamiento de condiciones médicas y veterinarias que involucren MC1R.
MX2013012525A 2008-05-27 2009-03-20 Análogos de péptido de la hormona de estimulación de alfa-melanocito. MX356295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5637308P 2008-05-27 2008-05-27
PCT/US2009/037809 WO2009151708A2 (en) 2008-05-27 2009-03-20 Peptide analogs of alpha-melanocyte stimulating hormone

Publications (1)

Publication Number Publication Date
MX356295B true MX356295B (es) 2018-05-22

Family

ID=41278142

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013012525A MX356295B (es) 2008-05-27 2009-03-20 Análogos de péptido de la hormona de estimulación de alfa-melanocito.
MX2010012990A MX2010012990A (es) 2008-05-27 2009-03-20 Analogos de peptido de la hormona de estimulacion de alfa-melanocito.
MX2018006299A MX2018006299A (es) 2008-05-27 2010-11-26 Analogos de peptido de la hormona de estimulacion de alfa-melanocito.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2010012990A MX2010012990A (es) 2008-05-27 2009-03-20 Analogos de peptido de la hormona de estimulacion de alfa-melanocito.
MX2018006299A MX2018006299A (es) 2008-05-27 2010-11-26 Analogos de peptido de la hormona de estimulacion de alfa-melanocito.

Country Status (16)

Country Link
US (4) US8440793B2 (es)
EP (2) EP2297178B1 (es)
JP (4) JP5624027B2 (es)
KR (4) KR20170102050A (es)
CN (2) CN102143970B (es)
AU (1) AU2009258054B2 (es)
BR (1) BRPI0912141A2 (es)
CA (2) CA2998948A1 (es)
DK (2) DK2297178T3 (es)
ES (2) ES2492670T3 (es)
IL (3) IL209369A (es)
MX (3) MX356295B (es)
PT (2) PT2816055T (es)
RU (1) RU2496786C2 (es)
TR (1) TR201903610T4 (es)
WO (1) WO2009151708A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170102050A (ko) * 2008-05-27 2017-09-06 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
CN101914138A (zh) * 2010-07-13 2010-12-15 华东师范大学 一种用偶联剂制得的肝癌靶向肽-阿霉素及合成方法
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
US9441013B2 (en) * 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
WO2014081845A2 (en) 2012-11-21 2014-05-30 University Of Cincinnati Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor
WO2015067503A1 (en) * 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
WO2016066702A1 (en) * 2014-10-28 2016-05-06 Clinuvel Ag Inflammatory disease
EP3328372A4 (en) 2015-07-28 2019-03-20 University Of Iowa Research Foundation COMPOSITIONS AND METHODS OF TREATING CANCER
SG10201506686WA (en) * 2015-08-24 2017-03-30 Agency Science Tech & Res Conjugates
CN106905432B (zh) * 2015-12-18 2018-12-21 兰州大学 一种α促黑素细胞激素的融合蛋白及其制备方法和应用
WO2017189860A1 (en) 2016-04-27 2017-11-02 The Regents Of The University Of California Preparation of functional homocysteine residues in polypeptides and peptides
EP3474879A4 (en) 2016-06-24 2020-05-06 University of Iowa Research Foundation COMPOSITIONS AND METHODS FOR TREATING MELANOMAS
EP3523316B1 (en) * 2016-10-04 2021-11-03 DSM IP Assets B.V. Melanocortin-1-receptor agonists
KR101957014B1 (ko) * 2017-04-18 2019-06-20 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
WO2021056106A1 (en) 2019-09-23 2021-04-01 Dds Research Inc. Lipid vesicle compositions with penetration enhancing agents
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
RU2766340C1 (ru) * 2021-02-10 2022-03-15 Игорь Закванович Зайцев Пептидный толерогенный компаунд
KR20240035939A (ko) * 2021-03-24 2024-03-19 글로 파마, 인크. 피부 색소침착을 감소시키기 위한 펩타이드 및 방법
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4952394A (en) * 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
AU725827B2 (en) * 1996-07-12 2000-10-19 Immunomedics Inc. Radiometal-binding peptide analogues
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20020193332A1 (en) * 2001-02-12 2002-12-19 Hedley Mary Lynne Methods of treating bladder disorders
US6969702B2 (en) * 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2005120588A2 (en) * 2004-05-26 2005-12-22 The Curators Of The University Of Missouri Peptides delivered to cell nuclei
RU2439079C2 (ru) 2005-07-08 2012-01-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов
US20100009340A1 (en) * 2006-04-05 2010-01-14 The Regents Of The University Of California Compositions and methods for the analysis and treatment of aids wasting syndrome and immune cell dysfunction
FR2914646A1 (fr) * 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
US8069129B2 (en) * 2007-04-10 2011-11-29 Ab Initio Technology Llc Editing and compiling business rules
CN101302245B (zh) * 2007-05-09 2011-11-16 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体四肽类激动剂及其制备方法和用途
KR20170102050A (ko) * 2008-05-27 2017-09-06 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체

Also Published As

Publication number Publication date
IL245906A0 (en) 2016-07-31
EP2297178B1 (en) 2014-07-30
KR20170102050A (ko) 2017-09-06
US10385108B2 (en) 2019-08-20
RU2496786C2 (ru) 2013-10-27
AU2009258054A1 (en) 2009-12-17
DK2297178T3 (da) 2014-09-01
KR20180118250A (ko) 2018-10-30
CN102143970B (zh) 2017-02-08
EP2816055A1 (en) 2014-12-24
TR201903610T4 (tr) 2019-03-21
EP2297178A2 (en) 2011-03-23
JP6170019B2 (ja) 2017-07-26
JP2011521949A (ja) 2011-07-28
US9738698B2 (en) 2017-08-22
PT2297178E (pt) 2014-08-26
KR101810110B1 (ko) 2017-12-18
EP2816055B1 (en) 2018-12-19
PT2816055T (pt) 2019-03-18
ES2492670T3 (es) 2014-09-10
MX2010012990A (es) 2011-05-25
IL209369A0 (en) 2011-01-31
CN102143970A (zh) 2011-08-03
JP2019065053A (ja) 2019-04-25
BRPI0912141A2 (pt) 2016-07-26
JP2014210805A (ja) 2014-11-13
KR101666631B1 (ko) 2016-10-17
MX2018006299A (es) 2021-11-11
DK2816055T3 (en) 2019-04-01
CA2726076C (en) 2018-04-10
KR20160092046A (ko) 2016-08-03
WO2009151708A2 (en) 2009-12-17
JP5624027B2 (ja) 2014-11-12
ES2715329T3 (es) 2019-06-03
CN107098957A (zh) 2017-08-29
AU2009258054B2 (en) 2014-03-20
CA2998948A1 (en) 2009-12-17
JP6585099B2 (ja) 2019-10-02
US9115174B2 (en) 2015-08-25
IL209369A (en) 2017-05-29
KR20110050593A (ko) 2011-05-16
WO2009151708A3 (en) 2010-11-18
JP2017061573A (ja) 2017-03-30
US8440793B2 (en) 2013-05-14
US20170313756A1 (en) 2017-11-02
RU2010153217A (ru) 2012-07-10
IL252058A0 (en) 2017-07-31
US20160046688A1 (en) 2016-02-18
CA2726076A1 (en) 2009-12-17
US20130303452A1 (en) 2013-11-14
US20090297444A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
MX356295B (es) Análogos de péptido de la hormona de estimulación de alfa-melanocito.
EP2496245A4 (en) ANALOG OF PITUTIC ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHOD OF USE THEREOF
EA201390194A1 (ru) Улучшенный рекомбинантный фолликул-стимулирующий гормон человека
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
MY187047A (en) Selective pyy compounds and uses thereof
TW200744642A (en) Novel peptides for use in the treatment of obesity
MY153976A (en) Lh liquid formulations
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
GB2471588A (en) Therapeutic peptidomimetic macrocycles
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
MX2010005451A (es) Sistema para la liberacion en una celula positiva para xcr1 y usos de este.
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
WO2011057027A3 (en) Method for treating heart failure with stresscopin-like peptides
WO2007093373A3 (en) Branched multimeric peptides for tumor diagnosis and therapy
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
TW200724679A (en) Treatment of disease using an improved regulated expression system
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.
PE20080674A1 (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
MD3885F1 (en) Method for polyparasitosis complex treatment to cattle
EP2370454A4 (en) PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM